Top Markets
#1 Black Phoenix Black Phoenix +827.90%
#2 PondCoin PondCoin +36.19%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.74%
#4 pipedog pipedog +28.59%
#5 SAFEcoin SAFEcoin +26.68%
#6 Bless Bless +24.96%
#7 Beam Beam +21.97%
#8 Seeker Seeker +21.81%
#9 Magma Finance Magma Finance +19.13%
#10 YFSX YFSX +16.11%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Rank in Stocks #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Share Price
$64.97
Last synced: 2024-05-20
Market Cap
$1.97B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Alpine Immune Sciences, Inc. (ALPN)

Category

Healthcare
P/E ratio for Alpine Immune Sciences, Inc. (ALPN)
P/E ratio as of August 2026 TTM: -101.52
According to Alpine Immune Sciences, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -101.52. At the end of 2022 the company had a P/E ratio of -4.25.
P/E ratio history for Alpine Immune Sciences, Inc. from 2012 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -101.52 242.84%
2023 -29.61 596.00%
2022 -4.25 -39.31%
2021 -7.01 -25.36%
2020 -9.39 466.64%
2019 -1.66 18.66%
2018 -1.40 -85.02%
2017 -9.33 745.71%
2016 -1.10 -65.30%
2015 -3.18 -64.89%
2014 -9.05 7.73%
2013 -8.40 -40.90%
2012 -14.22 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -128.76%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -130.16%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -131.98%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -92.18%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.